| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44AG072939 | Treatment of Complement-Mediated Myelitis | 000 | 1 | NIH | 6/20/2022 | $0 |
| | 2022 | 2021 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44HL156774 | Disease Modifying Treatment for Hemolytic Disorders | 000 | 1 | NIH | 10/19/2021 | $0 |
| | 2022 | 2017 | NOVELMED THERAPEUTICS, INC. | 11000 CEDAR AVE | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 000 | 3 | NIH | 12/16/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $833,165 ) |
| | 2021 | 2021 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44AG072939 | Treatment of Complement-Mediated Myelitis | 000 | 1 | NIH | 6/1/2021 | $300,000 |
| | 2021 | 2021 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44HL156774 | Disease Modifying Treatment for Hemolytic Disorders | 000 | 1 | NIH | 7/9/2021 | $533,165 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2017 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 000 | 3 | NIH | 9/24/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2017 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 000 | 3 | NIH | 3/7/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,277,607 ) |
| | 2017 | 2017 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 000 | 3 | NIH | 2/28/2017 | $1,277,607 |
| | 2017 | 2015 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44DK082025 | Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis | 000 | 3 | NIH | 12/7/2016 | $0 |
| | 2017 | 2014 | NOVELMED THERAPEUTICS INC | 11000 CEDAR AVENUE, 135 | CLEVELAND | OH | 44106-3007 | CUYAHOGA | USA | R44EY024809 | Single Therapy for Wet AMD & Geographic Atrophy | 000 | 1 | NIH | 6/21/2017 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $1,800,598 ) |
| | 2015 | 2015 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44DK082025 | Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis | 000 | 3 | NIH | 9/4/2015 | $601,912 |
| | 2015 | 2015 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 000 | 2 | NIH | 3/20/2015 | $1,159,286 |
| | 2015 | 2015 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44EY024809 | Single Therapy for Wet AMD & Geographic Atrophy | 001 | 1 | NIH | 9/15/2015 | $39,400 |
| | 2015 | 2014 | NOVELMED THERAPEUTICS INC | 2265 ENTERPRISE PARKWAY EAST | CLEVELAND | OH | 44087 | | USA | R44EY024809 | Single Therapy for Wet AMD & Geographic Atrophy | 000 | 1 | NIH | 8/17/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $3,069,358 ) |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 000 | 1 | NIH | 2/21/2014 | $421,050 |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL122028 | Preclinical and Clinical Evaluation of Humanized NM9405 | 001 | 1 | NIH | 5/20/2014 | $46,782 |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL115909 | Alternative Pathway Inhibitors for Orphan Indication | 000 | 2 | NIH | 8/1/2014 | $889,438 |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44EY019191 | Complement Inhibitors for Macular Degeneration | 000 | 3 | NIH | 3/28/2014 | $239,000 |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44EY019191 | Complement Inhibitors for Macular Degeneration | 001 | 3 | NIH | 8/26/2014 | $25,000 |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44DK082025 | Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis | 000 | 2 | NIH | 7/23/2014 | $849,661 |
| | 2014 | 2014 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44EY024809 | Single Therapy for Wet AMD & Geographic Atrophy | 000 | 1 | NIH | 9/15/2014 | $548,724 |
| | 2014 | 2012 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44AG039118 | Disease Modifying Biologics for Rheumatoid Arthritis | 000 | 3 | NIH | 11/7/2013 | $49,703 |
|
| Issue Date FY: 2013 ( Subtotal = $1,527,089 ) |
| | 2013 | 2013 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44EY019191 | Complement Inhibitors for Macular Degeneration | 000 | 3 | NIH | 7/11/2013 | $597,897 |
| | 2013 | 2013 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44AG041564 | COMPLEMENT INHIBITORS AS DMOADS | 000 | 2 | NIH | 8/6/2013 | $307,870 |
| | 2013 | 2013 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL115909 | Alternative Pathway Inhibitors for Orphan Indication | 000 | 1 | NIH | 8/1/2013 | $542,572 |
| | 2013 | 2013 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44AG041564 | COMPLEMENT INHIBITORS AS DMOADS | 001 | 2 | NIH | 9/10/2013 | $78,750 |
| | 2013 | 2010 | NOVELMED THERAPEUTICS INC | 2265 ENTERPRISE PARKWAY EAST | CLEVELAND | OH | 44087 | | USA | R43GM090341 | DEVICE FOR SURGICAL ADHESION PREVENTION | 000 | 1 | NIH | 11/21/2012 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $3,004,577 ) |
| | 2012 | 2012 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44AG039118 | Disease Modifying Biologics for Rheumatoid Arthritis | 000 | 3 | NIH | 3/30/2012 | $918,767 |
| | 2012 | 2012 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL099015 | CONTROLLING INFLAMMATION DUE TO CARDIAC DEVICES | 000 | 3 | NIH | 7/12/2012 | $633,313 |
| | 2012 | 2012 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44EY019191 | Complement Inhibitors for Macular Degeneration | 000 | 2 | NIH | 7/16/2012 | $466,354 |
| | 2012 | 2012 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44AG041564 | COMPLEMENT INHIBITORS AS DMOADS | 000 | 1 | NIH | 7/17/2012 | $294,766 |
| | 2012 | 2012 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL102890 | INHIBITION OF CARDIAC DEVICE INDUCED CELLULAR DYSFUNCTION IN PIGS | 000 | 3 | NIH | 8/7/2012 | $691,377 |
| | 2012 | 2010 | NOVELMED THERAPEUTICS INC | 2265 ENTERPRISE PARKWAY EAST | CLEVELAND | OH | 44087 | | USA | R43AI085697 | NEUTRALIZING ANTIBODIES FOR COMPLEMENT INHIBITION | 000 | 1 | NIH | 7/13/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $2,152,085 ) |
| | 2011 | 2011 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL099015 | CONTROLLING INFLAMMATION DUE TO CARDIAC DEVICES | 000 | 2 | NIH | 7/30/2011 | $719,654 |
| | 2011 | 2011 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL102890 | INHIBITION OF CARDIAC DEVICE INDUCED CELLULAR DYSFUNCTION IN PIGS | 000 | 2 | NIH | 8/18/2011 | $503,352 |
| | 2011 | 2011 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44AG039118 | Disease Modifying Biologics for Rheumatoid Arthritis | 000 | 2 | NIH | 4/8/2011 | $929,079 |
| | 2011 | 2010 | NOVELMED THERAPEUTICS INC | 2265 ENTERPRISE PARKWAY EAST | CLEVELAND | OH | 44087 | | USA | R43AI085697 | NEUTRALIZING ANTIBODIES FOR COMPLEMENT INHIBITION | 000 | 1 | NIH | 8/2/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $2,293,995 ) (Continued on the next page) |
| | 2010 | 2010 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R43GM090341 | DEVICE FOR SURGICAL ADHESION PREVENTION | 000 | 1 | NIH | 9/13/2010 | $266,001 |
| | 2010 | 2010 | NOVELMED THERAPEUTICS INC | 11000 Cedar Ave Ste 135 | Cleveland | OH | 44106-3007 | CUYAHOGA | USA | R44HL102890 | INHIBITION OF CARDIAC DEVICE INDUCED CELLULAR DYSFUNCTION IN PIGS | 000 | 1 | NIH | 8/17/2010 | $516,118 |
|
